AU2019329984A1 - Methods and compositions for adoptive T cell therapy incorporating induced notch signaling - Google Patents

Methods and compositions for adoptive T cell therapy incorporating induced notch signaling Download PDF

Info

Publication number
AU2019329984A1
AU2019329984A1 AU2019329984A AU2019329984A AU2019329984A1 AU 2019329984 A1 AU2019329984 A1 AU 2019329984A1 AU 2019329984 A AU2019329984 A AU 2019329984A AU 2019329984 A AU2019329984 A AU 2019329984A AU 2019329984 A1 AU2019329984 A1 AU 2019329984A1
Authority
AU
Australia
Prior art keywords
cells
cell
notch
exposing
days
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
AU2019329984A
Other languages
English (en)
Inventor
Irwin D. Bernstein
Margot J. PONT
Stanley R. Riddell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fred Hutchinson Cancer Center
Original Assignee
Fred Hutchinson Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fred Hutchinson Cancer Center filed Critical Fred Hutchinson Cancer Center
Publication of AU2019329984A1 publication Critical patent/AU2019329984A1/en
Assigned to FRED HUTCHINSON CANCER CENTER reassignment FRED HUTCHINSON CANCER CENTER Request for Assignment Assignors: FRED HUTCHINSON CANCER RESEARCH CENTER
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/25—Tumour necrosing factors [TNF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/42—Notch; Delta; Jagged; Serrate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
AU2019329984A 2018-08-28 2019-08-28 Methods and compositions for adoptive T cell therapy incorporating induced notch signaling Withdrawn AU2019329984A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862723936P 2018-08-28 2018-08-28
US62/723,936 2018-08-28
PCT/US2019/048574 WO2020047099A1 (en) 2018-08-28 2019-08-28 Methods and compositions for adoptive t cell therapy incorporating induced notch signaling

Publications (1)

Publication Number Publication Date
AU2019329984A1 true AU2019329984A1 (en) 2021-03-11

Family

ID=67982131

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019329984A Withdrawn AU2019329984A1 (en) 2018-08-28 2019-08-28 Methods and compositions for adoptive T cell therapy incorporating induced notch signaling

Country Status (9)

Country Link
US (1) US20210292711A1 (cg-RX-API-DMAC7.html)
EP (1) EP3844266A1 (cg-RX-API-DMAC7.html)
JP (1) JP2021534785A (cg-RX-API-DMAC7.html)
CN (1) CN112930393A (cg-RX-API-DMAC7.html)
AU (1) AU2019329984A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021003830A2 (cg-RX-API-DMAC7.html)
CA (1) CA3110089A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202101455TA (cg-RX-API-DMAC7.html)
WO (1) WO2020047099A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12624072B2 (en) 2019-05-01 2026-05-12 H. Lee Moffitt Cancer Center And Research Institute, Inc. Engineering broadly reactive human notch ligands as novel tools for biomedical applications
US20220241335A1 (en) * 2019-07-11 2022-08-04 H. Lee Moffitt Cancer Center And Research Inst5Itute, Inc. Engineering notch ligands to enhance the anti-tumor activity of adoptively transferred t cells
WO2021222479A1 (en) 2020-04-28 2021-11-04 Lyell Immunopharma, Inc. Methods for culturing cells
WO2022165367A1 (en) * 2021-01-29 2022-08-04 Fred Hutchinson Cancer Research Center Methods and compositions for enhancing cd4+ phenotype for adoptive t cell therapy
CN113832102B (zh) * 2021-09-27 2024-03-12 苏州东岭生物技术有限公司 Cd3/cd28/dll4磁珠及其制备方法和应用
CN116716349B (zh) * 2023-08-01 2023-10-31 江苏集萃药康生物科技股份有限公司 一种dll4人源化小鼠模型的构建方法及其应用

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA136551A (en) 1911-08-03 1911-10-31 Hedwig Heeron Rolling mill
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
IE20030749A1 (en) 1991-05-03 2003-11-12 Indiana University Foundation Human notch and delta binding domains in torporythmic proteins, and methods based thereon
US5420032A (en) 1991-12-23 1995-05-30 Universitge Laval Homing endonuclease which originates from chlamydomonas eugametos and recognizes and cleaves a 15, 17 or 19 degenerate double stranded nucleotide sequence
US5792632A (en) 1992-05-05 1998-08-11 Institut Pasteur Nucleotide sequence encoding the enzyme I-SceI and the uses thereof
US5780300A (en) 1995-09-29 1998-07-14 Yale University Manipulation of non-terminally differentiated cells using the notch pathway
US6451995B1 (en) 1996-03-20 2002-09-17 Sloan-Kettering Institute For Cancer Research Single chain FV polynucleotide or peptide constructs of anti-ganglioside GD2 antibodies, cells expressing same and related methods
EP1616958A3 (en) * 1996-11-07 2006-02-08 Lorantis Limited Notch-ligands for use in immunotherapy
WO2000014257A1 (en) 1998-09-04 2000-03-16 Sloan-Kettering Institute For Cancer Research Fusion receptors specific for prostate-specific membrane antigen and uses thereof
CA2410510A1 (en) 2000-06-02 2001-12-13 Memorial Sloan-Kettering Cancer Center Artificial antigen presenting cells and methods of use thereof
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
US6689744B2 (en) 2000-09-22 2004-02-10 Genentech, Inc. Notch receptor agonists and uses
US20030119771A1 (en) 2001-08-22 2003-06-26 Rompaey Luc Van Modulators of bone homeostasis identified in a high-throughput screen
JP2003093048A (ja) * 2001-09-26 2003-04-02 Asahi Kasei Corp 新規細胞製剤製造用培養媒体
US20030170238A1 (en) 2002-03-07 2003-09-11 Gruenberg Micheal L. Re-activated T-cells for adoptive immunotherapy
US8206965B2 (en) 2002-03-15 2012-06-26 Cellectis S.A. Hybrid and single chain meganucleases and use thereof
EP1492816A2 (en) * 2002-04-05 2005-01-05 Lorantis Limited Modulators of the notch signalling pathway and uses thereof in medical treatment
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
JP2006513153A (ja) * 2002-10-09 2006-04-20 ロランティス リミテッド 免疫機能の調節
WO2004064863A1 (en) * 2003-01-23 2004-08-05 Lorantis Limited Treatment of autoimmune diseases using an activator for the notch signaling pathway
US20060206949A1 (en) 2003-01-28 2006-09-14 Sylvain Arnould Custom-made meganuclease and use thereof
CA2589279A1 (en) * 2004-11-24 2006-06-01 Val-Chum, S.E.C. Methods to identify, prepare, and use naive t cell recent thymic emigrants
WO2007027226A2 (en) * 2005-04-28 2007-03-08 Board Of Regents, The University Of Texas System Systems and methods for the production of differentiated cells
DK3246403T3 (da) 2005-10-18 2020-10-26 Prec Biosciences Rationelt designede meganucleaser med ændret sekvens-specificitet og dna-bindende affinitet
EP2081962B1 (en) 2006-10-19 2018-10-03 Genentech, Inc. Novel anti-notch3 antibodies and their use in the detection and diagnosis of disease
JP5478254B2 (ja) 2006-10-19 2014-04-23 ジェネンテック, インコーポレイテッド 抗ノッチ3アゴニスト抗体とノッチ3関連疾患の治療におけるその使用
WO2008092445A2 (de) * 2007-01-30 2008-08-07 Deutsches Rheuma-Forschungszentrum Berlin Verfahren zur modulation der immunantwort durch aktivierung oder inaktivierung des notch und/oder stat4 signalweges
US8389282B2 (en) 2007-03-30 2013-03-05 Memorial Sloan-Kettering Cancer Center Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes
US9221902B2 (en) 2008-11-07 2015-12-29 Fabrus, Inc. Combinatorial antibody libraries and uses thereof
WO2010059543A1 (en) 2008-11-20 2010-05-27 Merck Sharp & Dohme Corp. Generation and characterization of anti-notch antibodies for therapeutic and diagnostic use
WO2010141249A2 (en) 2009-06-02 2010-12-09 Merck Sharp & Dohme Corp. Generation, characterization and uses thereof of anti-notch3 antibodies
AU2011256838B2 (en) 2010-05-17 2014-10-09 Sangamo Therapeutics, Inc. Novel DNA-binding proteins and uses thereof
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
WO2013126726A1 (en) 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Double transgenic t cells comprising a car and a tcr and their methods of use
ES2728782T3 (es) 2012-05-25 2019-10-28 Univ California Métodos y composiciones para la modificación de ADN objetivo dirigida por ARN y para la modulación de la transcripción dirigida por ARN
US10316289B2 (en) * 2012-09-06 2019-06-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of producing T memory stem cell populations
EP3064585B1 (en) 2012-12-12 2020-02-05 The Broad Institute, Inc. Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
US10696946B2 (en) * 2013-02-22 2020-06-30 The Board Of Trustees Of The University Of Illinois T-REG cell expansion
US9683039B2 (en) 2013-03-14 2017-06-20 New York University Notch agonists for the treatment of cancer
EP3760719A1 (en) 2013-11-18 2021-01-06 CRISPR Therapeutics AG Crispr-cas system materials and methods
WO2015179633A1 (en) 2014-05-22 2015-11-26 Fred Hutchinson Cancer Research Center Lilrb2 and notch-mediated expansion of hematopoietic precursor cells
KR102382905B1 (ko) 2014-06-04 2022-04-04 프레드 헛친슨 켄서 리서치 센터 노치 1 및/또는 노치 2 작용제를 사용한 줄기 세포의 확장 및 생착
RU2716716C2 (ru) * 2014-10-27 2020-03-16 Фред Хатчинсон Кэнсер Рисёрч Сентер Композиции и способы для бустинга эффективности адоптивной клеточной иммунотерапии
WO2017070333A1 (en) * 2015-10-20 2017-04-27 Cellular Dynamics International, Inc. Multi-lineage hematopoietic precursor cell production by genetic programming
KR102908806B1 (ko) * 2015-10-22 2026-01-07 주노 테라퓨틱스 게엠베하 세포의 배양 방법 및 이를 위한 키트와 장치
KR102929174B1 (ko) * 2015-10-30 2026-02-20 더 리전츠 오브 더 유니버시티 오브 캘리포니아 줄기세포로부터 t-세포를 생산하는 방법 및 상기 t-세포를 이용한 면역치료 방법
US12076342B2 (en) * 2016-04-08 2024-09-03 The Governing Council Of The University Of Toronto Method for generating progenitor t cells from stem and/or progenitor cells and use of same
WO2018017827A1 (en) 2016-07-22 2018-01-25 Fred Hutchinson Cancer Research Center Bi-specific molecule for cell-specific notch inhibition and related methods and compositions

Also Published As

Publication number Publication date
WO2020047099A1 (en) 2020-03-05
US20210292711A1 (en) 2021-09-23
BR112021003830A2 (pt) 2021-07-20
CA3110089A1 (en) 2020-03-05
EP3844266A1 (en) 2021-07-07
CN112930393A (zh) 2021-06-08
JP2021534785A (ja) 2021-12-16
SG11202101455TA (en) 2021-03-30

Similar Documents

Publication Publication Date Title
US20250114433A1 (en) Binding proteins specific for ras neoantigens and uses thereof
US11034748B2 (en) High affinity MAGE-A1-specific TCRs and uses thereof
AU2015295349B2 (en) ROR1(NTRKR1)specific chimeric antigen receptors for cancer immunotherapy
US20210292711A1 (en) Methods and compositions for adoptive t cell therapy incorporating induced notch signaling
CN110997902B (zh) Suv39h1缺陷的免疫细胞
US20210069241A1 (en) Compositions and methods of immunotherapy targeting tigit and/or cd112r or comprising cd226 overexpression
US20240165232A1 (en) Chimeric receptor proteins and uses thereof
US11786550B2 (en) gRNA targeting HPK1 and a method for editing HPK1 gene
JP2023078376A (ja) 遺伝子療法
KR20170002412A (ko) 암 면역요법을 위한 cd33 특이적 키메라 항원 수용체들
US20230052243A1 (en) Nr4a-deficient cells expressing c-jun and uses thereof
TW202402798A (zh) 對新抗原具特異性之結合蛋白與工程化細胞及其用途
JP2020535796A (ja) strepタグ特異的キメラ受容体およびその使用
US20220267403A1 (en) Binding proteins specific for 5t4 and uses thereof
JP2024520492A (ja) Nr4a3欠損免疫細胞及びその使用
JP7737978B2 (ja) Wt-1に特異的なt細胞免疫療法
US20220411479A1 (en) Cd20 chimeric antigen receptors and methods of use for immunotherapy
JP2025516627A (ja) Rasネオ抗原に特異的な結合タンパク質及びその使用
WO2022165367A1 (en) Methods and compositions for enhancing cd4+ phenotype for adoptive t cell therapy
WO2022076353A1 (en) Compositions and methods for treating mage-a1-expressing disease
Caruso Car-Modified T Cells Capable of Distinguishing Normal Cells From Malignant Cells
HK40017846A (en) Immune cells defective for suv39h1

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: FRED HUTCHINSON CANCER CENTER

Free format text: FORMER APPLICANT(S): FRED HUTCHINSON CANCER RESEARCH CENTER

MK12 Application lapsed section 141(1)/reg 8.3(2) - applicant filed a written notice of withdrawal